Lipocine LPCN Stock
Lipocine Price Chart
Lipocine LPCN Financial and Trading Overview
| Lipocine stock price | 6.59 USD |
| Previous Close | 4.79 USD |
| Open | 4.85 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 1400 |
| Day's Range | 4.74 - 5.22 USD |
| 52 Week Range | 3.3 - 14.81 USD |
| Volume | 14.62K USD |
| Avg. Volume | 26.34K USD |
| Market Cap | 26.19M USD |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.33 USD |
LPCN Valuation Measures
| Enterprise Value | -3602818 USD |
| Trailing P/E | N/A |
| Forward P/E | -2.9415205 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 47.18787 |
| Price/Book (mrq) | 0.8194852 |
| Enterprise Value/Revenue | -6.492 |
| Enterprise Value/EBITDA | 0.271 |
Trading Information
Lipocine Stock Price History
| Beta (5Y Monthly) | 0.95 |
| 52-Week Change | -63.42% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.81 USD |
| 52 Week Low | 3.3 USD |
| 50-Day Moving Average | 4.64 USD |
| 200-Day Moving Average | 6.92 USD |
LPCN Share Statistics
| Avg. Volume (3 month) | 26.34K USD |
| Avg. Daily Volume (10-Days) | 13.66K USD |
| Shares Outstanding | 5.21M |
| Float | 5.04M |
| Short Ratio | 1.92 |
| % Held by Insiders | N/A |
| % Held by Institutions | N/A |
| Shares Short | 108.5K |
| Short % of Float | 2.14% |
| Short % of Shares Outstanding | 2.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:17 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2401.19% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.40% |
| Return on Equity (ttm) | -29.96% |
Income Statement
| Revenue (ttm) | 554.99K USD |
| Revenue Per Share (ttm) | 0.11 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 500K USD |
| EBITDA | -13313815 USD |
| Net Income Avi to Common (ttm) | -11141174 USD |
| Diluted EPS (ttm) | -2.43 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 28.87M USD |
| Total Cash Per Share (mrq) | 5.55 USD |
| Total Debt (mrq) | 327.58K USD |
| Total Debt/Equity (mrq) | 1.03 USD |
| Current Ratio (mrq) | 15.862 |
| Book Value Per Share (mrq) | 6.138 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12011474 USD |
| Levered Free Cash Flow (ttm) | -8156768 USD |
Profile of Lipocine
| Country | United States |
| State | UT |
| City | Salt Lake City |
| Address | 675 Arapeen Drive |
| ZIP | 84108 |
| Phone | 801 994 7383 |
| Website | https://www.lipocine.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Q&A For Lipocine Stock
What is a current LPCN stock price?
Lipocine LPCN stock price today per share is 6.59 USD.
How to purchase Lipocine stock?
You can buy LPCN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lipocine?
The stock symbol or ticker of Lipocine is LPCN.
Which industry does the Lipocine company belong to?
The Lipocine industry is Biotechnology.
How many shares does Lipocine have in circulation?
The max supply of Lipocine shares is 5.35M.
What is Lipocine Price to Earnings Ratio (PE Ratio)?
Lipocine PE Ratio is now.
What was Lipocine earnings per share over the trailing 12 months (TTM)?
Lipocine EPS is -1.72 USD over the trailing 12 months.
Which sector does the Lipocine company belong to?
The Lipocine sector is Healthcare.
Lipocine LPCN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| NASDAQ Composite Total Return I XCMP | 20585.06 USD — |
-0.58
|
— — | 20528.35 USD — | 20669.02 USD — | — - | — — |
| NASDAQ Industrial INDS | 37.4 USD — |
+1.36
|
5.71K USD — | 9710.55 USD — | 9776 USD — | — - | 5.71K USD — |
| NASDAQ Capital Market Composite RCMP | 111.05 USD — |
-1.6
|
— — | 110.9 USD — | 111.54 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 967.78 USD — |
-1.12
|
— — | 964.91 USD — | 969.79 USD — | — - | — — |
- {{ link.label }} {{link}}